The American College of Rheumatology (ACR) applauds the decision from the Centers for Medicare & Medicaid Services (CMS) not to go forward with the agency’s controversial Part B payment proposal, noting that the hard-fought outcome is good news for rheumatology patients who rely on Medicare Part B to access life-saving biologic therapies.
“We thank CMS for listening to the rheumatology community’s concerns about the negative and disproportionate impact this proposal would have on our Medicare patients living with rheumatic diseases by not moving forward with this Part B Demonstration Project,” said Dr. Sharad Lakhanpal, MBBS, MD, President of the ACR.
